Pfizer, Novartis join forces to develop new NASH therapies

Pfizer and Novartis have jointly announced today that they have entered into an agreement aimed at developing new therapies for the treatment of non-alcoholic steatohepatitis (NASH), a business likely to deliver at least $35bn in sales, many experts say.

Under the agreement, some promising investigational drugs developed by Pfizer and not tested yet will be submitted to clinical trials. These are PF-05221304, DGAT2 and a ketohexokinase (KHK) inhibitor, which will be tested in combination with Novartis’ tropifexor.

Importantly, Intercept Pharmaceutics probably has a strong advantage over Pfizer and Novartis, as it is expected to market its NASH therapy–obeticholic acid–as early as next year.

(Source: Pfizer)